Illumina Partners with MyOme to Advance AI-Driven Genomic Health Solutions

Reuters12-11

<a href="https://laohu8.com/S/ILMN">Illumina</a> Partners with MyOme to Advance AI-Driven <a href="https://laohu8.com/S/GHDX">Genomic Health</a> Solutions

Illumina Inc. has announced a collaboration and strategic investment with MyOme, a genomics innovation and risk modeling company. The partnership aims to advance MyOme's Proactive Health (MPH) Trial, a large-scale clinical trial designed to demonstrate the benefits of using whole-genome sequencing combined with MyOme's AI-integrated risk models for early detection and prevention of common, chronic conditions, cancers, and rare diseases. Illumina's leading sequencing technology will be integrated with MyOme's advanced bioinformatics and risk models to deliver improved patient outcomes and significant healthcare cost savings. The collaboration also supports the expansion of MyOme's diagnostic products, including proactive health and rare disease tests, with the goal of providing more accurate, ancestry-relevant risk assessments for a wide range of diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA44244) on December 11, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590511293?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 22:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590511293","market":"nz","top_or_hot":-1,"title":"Illumina Partners with MyOme to Advance AI-Driven Genomic Health Solutions","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ILMN\">Illumina</a> Partners with MyOme to Advance AI-Driven <a href=\"https://laohu8.com/S/GHDX\">Genomic Health</a> Solutions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ILMNV\">Illumina Inc</a>. has announced a collaboration and strategic investment with MyOme, a genomics innovation and risk modeling company. The partnership aims to advance MyOme's Proactive Health (MPH) Trial, a large-scale clinical trial designed to demonstrate the benefits of using whole-genome sequencing combined with MyOme's AI-integrated risk models for early detection and prevention of common, chronic conditions, cancers, and rare diseases. Illumina's leading sequencing technology will be integrated with MyOme's advanced bioinformatics and risk models to deliver improved patient outcomes and significant healthcare cost savings. The collaboration also supports the expansion of MyOme's diagnostic products, including proactive health and rare disease tests, with the goal of providing more accurate, ancestry-relevant risk assessments for a wide range of diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA44244) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Illumina Partners with MyOme to Advance AI-Driven Genomic Health Solutions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIllumina Partners with MyOme to Advance AI-Driven Genomic Health Solutions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-11 22:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ILMN\">Illumina</a> Partners with MyOme to Advance AI-Driven <a href=\"https://laohu8.com/S/GHDX\">Genomic Health</a> Solutions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ILMNV\">Illumina Inc</a>. has announced a collaboration and strategic investment with MyOme, a genomics innovation and risk modeling company. The partnership aims to advance MyOme's Proactive Health (MPH) Trial, a large-scale clinical trial designed to demonstrate the benefits of using whole-genome sequencing combined with MyOme's AI-integrated risk models for early detection and prevention of common, chronic conditions, cancers, and rare diseases. Illumina's leading sequencing technology will be integrated with MyOme's advanced bioinformatics and risk models to deliver improved patient outcomes and significant healthcare cost savings. The collaboration also supports the expansion of MyOme's diagnostic products, including proactive health and rare disease tests, with the goal of providing more accurate, ancestry-relevant risk assessments for a wide range of diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA44244) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLbfqk3z:1","article_id":"2590511293","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590511293","pubTimestamp":1765462522,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Illumina Inc. has announced a collaboration and strategic investment with MyOme, a genomics innovation and risk modeling company. The partnership aims to advance MyOme's Proactive Health  Trial, a large-scale clinical trial designed to demonstrate the benefits of using whole-genome sequencing combined with MyOme's AI-integrated risk models for early detection and prevention of common, chronic conditions, cancers, and rare diseases. Illumina's leading sequencing technology will be integrated with MyOme's advanced bioinformatics and risk models to deliver improved patient outcomes and significant healthcare cost savings. The collaboration also supports the expansion of MyOme's diagnostic products, including proactive health and rare disease tests, with the goal of providing more accurate, ancestry-relevant risk assessments for a wide range of diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ac","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4585":"ETF&股票定投概念","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4535":"淡马锡持仓","BK4139":"生物科技","EXAS":"精密科学","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4121":"生命科学工具和服务","LU1861558580.USD":"日兴方舟颠覆性创新基金B","ILMN":"Illumina","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4588":"碎股","BK4534":"瑞士信贷持仓"},"translate_title":"Illumina与MyOme合作推进人工智能驱动的基因组健康解决方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXAS":0.9,"ILMN":0.9},"content_text":"Illumina Partners with MyOme to Advance AI-Driven Genomic Health Solutions\n    \n\nIllumina Inc. has announced a collaboration and strategic investment with MyOme, a genomics innovation and risk modeling company. The partnership aims to advance MyOme's Proactive Health (MPH) Trial, a large-scale clinical trial designed to demonstrate the benefits of using whole-genome sequencing combined with MyOme's AI-integrated risk models for early detection and prevention of common, chronic conditions, cancers, and rare diseases. Illumina's leading sequencing technology will be integrated with MyOme's advanced bioinformatics and risk models to deliver improved patient outcomes and significant healthcare cost savings. The collaboration also supports the expansion of MyOme's diagnostic products, including proactive health and rare disease tests, with the goal of providing more accurate, ancestry-relevant risk assessments for a wide range of diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA44244) on December 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590511293","isCrawlerRequest":true}